Why Innovative Devices Face Harder Clinical Scrutiny Than Me-Toos

Written by HATEM RABEH, MD, MSc Ing

Your Clinical Evaluation Expert And Partner

in
S

Most manufacturers assume clinical evaluation is a fixed burden tied to device classification. You gather literature. You write state of the art. You submit PMCF plans. Done.

That assumption breaks when your device introduces something genuinely new.

The MDR does not treat all devices equally when it comes to clinical evidence. Article 61(4) and (5) explicitly distinguish between devices with sufficient clinical evidence available and those without. MDCG 2020-13 on clinical evaluation goes further, separating the pathway for innovative devices from devices relying on equivalence or existing clinical data.

The practical consequence? Two devices in the same risk class can face radically different scrutiny depending on how novel they are.

What Makes a Device Innovative in Regulatory Terms

Innovation is not about marketing claims. It is about clinical data availability.

A device is innovative when there is no sufficient body of clinical evidence available for devices with similar technical, biological, and clinical characteristics. This is the language of MDR Annex XIV Part A Section 1.

What qualifies as insufficient evidence? Any situation where:

• The technology is genuinely new and not clinically documented
• The clinical application is novel even if the technology is familiar
• The intended patient population has not been studied with this type of device
• The duration of use or mode of interaction with tissue differs significantly from existing data

The last point catches many teams off guard. You can introduce a me-too device and still be classified as innovative if you apply it differently.

Example: A surgical mesh with a familiar polymer composition used in a new anatomical site may require clinical investigation even if the same polymer is well documented in other applications.

The Me-Too Device Pathway

Me-too devices benefit from existing clinical data. They do not introduce new risks. They do not claim superior performance that requires proof. They follow established clinical patterns.

For these devices, clinical evaluation relies on:

• Demonstration of equivalence to a well-documented device
• Appraisal of published literature covering the same technical and clinical characteristics
• PMCF to confirm ongoing safety and performance in real-world use

Equivalence is central here. MDR Annex XIV Part A Section 3 defines equivalence across technical, biological, and clinical dimensions. If you can demonstrate that your device is equivalent to one with sufficient clinical data, you can leverage that data.

This is the most resource-efficient pathway. You avoid pre-market clinical investigations. You reduce time to market. You minimize cost.

But equivalence is narrow and brittle. It breaks with any meaningful change in design, material, intended use, or patient population.

When Equivalence Collapses

Most disputes I see during audits happen at the boundary. The manufacturer believes the device is me-too. The reviewer sees gaps in the equivalence claim.

The most frequent failure points:

Material differences dismissed as minor. You change the surface coating. You argue it does not affect performance. The reviewer asks: where is the clinical evidence that this coating behaves the same way in vivo? If you cannot answer with data, equivalence fails.

Duration of use extended without justification. Your predicate device was used for short-term application. Yours is intended for chronic use. You cite the same literature. Reviewers will not accept this. Long-term interaction with tissue introduces risks not covered by short-term studies.

Patient population broadened without supporting data. You add pediatric indications to an adult device. You argue the physiology is similar. Reviewers expect evidence specific to pediatric anatomy, compliance, and safety. Without it, equivalence is invalid.

Here is what happens when equivalence collapses: your device is reclassified as innovative mid-review. Your clinical evaluation report is rejected. You are told to conduct a clinical investigation.

This is not theoretical. I have seen submissions delayed by twelve months or more because the equivalence strategy was assumed valid without rigorous justification.

The Clinical Investigation Requirement for Innovative Devices

For truly innovative devices, clinical investigation is the default expectation. MDCG 2020-13 is explicit here. When sufficient clinical evidence does not exist, you must generate it.

This shifts the entire development timeline. Clinical investigations require:

• Ethics committee approval
• Competent authority notification or approval depending on jurisdiction
• Investigational device compliance with Annex XV of the MDR
• Clinical investigation plan aligned with ISO 14155
• Post-investigation reporting and integration into your CER

The evidence burden is higher. Literature alone will not suffice. You need primary data showing your device is safe and performs as intended in the target population under real conditions of use.

Many manufacturers delay this decision. They try to stretch equivalence arguments. They submit CEPs hoping reviewers will accept marginal claims. This strategy fails more often than it succeeds.

How Notified Bodies Assess Innovation Level

Notified Bodies do not accept your self-assessment at face value. They conduct their own evaluation of innovation level during the clinical evaluation review.

Their reasoning follows a structured path:

First, they review your equivalence claim if you made one. They check the technical, biological, and clinical comparison tables. They assess whether the predicate device truly has sufficient clinical data. They look for gaps in the comparison.

Second, they appraise the literature you cited. They ask: does this literature cover the specific risks and performance claims of your device? If your device introduces any new element—material, geometry, energy source, mode of action—they expect literature specific to that element.

Third, they evaluate the clinical data availability for your target population and intended use. If your device is used in a vulnerable population or a high-risk anatomical site, they expect more robust evidence even if the technology seems familiar.

Fourth, they apply the MDR Annex XIV framework. If any of the three dimensions of equivalence—technical, biological, clinical—cannot be fully demonstrated, they conclude your device is innovative.

This is not a subjective judgment. It is a structured assessment based on regulatory text and guidance.

When Notified Bodies conclude your device is innovative, they issue a finding. You must respond with a clinical investigation plan or withdraw the submission.

Strategic Implications for Your Clinical Evaluation

Understanding innovation level early changes how you build your clinical evaluation.

If your device is me-too, invest in a rigorous equivalence demonstration. Do not assume similarity. Prove it with detailed comparative analysis and targeted literature. Make sure your PMCF plan addresses any residual uncertainties.

If your device is innovative, do not waste time on weak equivalence arguments. Accept that you need primary clinical data. Plan your investigation early. Align your development timeline with regulatory reality.

The worst position is ambiguity. You submit a CER that straddles both pathways. You claim equivalence but acknowledge gaps. You cite literature but admit it does not fully cover your device. Reviewers see this as incomplete preparation. They reject the submission and ask for clarity.

Ambiguity costs time. Clarity accelerates approval.

The Role of PMCF in Both Pathways

Post-market clinical follow-up is mandatory for both innovative and me-too devices, but the objectives differ.

For me-too devices, PMCF confirms that the clinical evidence used in your pre-market evaluation remains valid. You are monitoring for deviations from expected performance. You are watching for emerging risks not seen in the literature. Your PMCF plan should be proportionate and targeted.

For innovative devices, PMCF is more intensive. You are generating long-term evidence for a device that had limited pre-market data. Your PMCF plan must address the uncertainties that remained after your clinical investigation. Reviewers expect more robust methods, larger datasets, and longer follow-up periods.

The distinction matters for resource planning. A me-too device may require registry participation and periodic literature surveillance. An innovative device may require a prospective PMCF study with active patient enrollment and structured endpoints.

What This Means for Your Next Submission

Before you begin your clinical evaluation, assess your innovation level honestly.

Ask: is there sufficient clinical evidence for devices with the same technical, biological, and clinical characteristics as mine?

If yes, prove equivalence rigorously. If no, plan for clinical investigation.

Do not rely on assumptions. Do not hope reviewers will be lenient. Do not submit a CER that leaves the question unresolved.

The regulatory system rewards clarity and penalizes ambiguity.

Innovation is not a weakness. It is a regulatory reality. Acknowledge it early and plan accordingly.

Peace,
Hatem
Clinical Evaluation Expert for Medical Devices
Follow me for more insights and practical advice.